Torben Frøstrup Hansen

Medicin og biovidenskab

1. Colorectal Neoplasms 100%
2. Colonic Neoplasms 74%
3. MicroRNAs 72%
4. Neoplasms 40%
5. Drug Therapy 35%
6. Bevacizumab 33%
7. Oxaliplatin 33%
8. Circulating Tumor DNA 32%
9. Rectal Neoplasms 31%
10. Survival 24%
11. Capecitabine 24%
12. Biomarkers 20%
13. Single Nucleotide Polymorphism 20%
14. Vascular Endothelial Growth Factor A 20%
15. Progression-Free Survival 18%
16. Therapeutics 18%
17. Biliary Tract Neoplasms 18%
18. Epidermal Growth Factor 16%
19. Circulating MicroRNA 15%
20. Prostatic Neoplasms 14%
21. Microvessels 14%
22. DNA 13%
23. Panitumumab 12%
24. Genes 12%
25. Confidence Intervals 12%
26. Recurrence 11%
27. Natural Killer Cells 11%
28. Vascular Endothelial Growth Factor Receptor-2 11%
29. Tumor-Infiltrating Lymphocytes 10%
30. Angiogenesis Inhibitors 10%
31. Population 10%
32. Microsatellite Instability 10%
33. XELOX 9%
34. Immunotherapy 9%
35. Combination Drug Therapy 9%
36. Bronchoalveolar Lavage 9%
37. Chemoradiotherapy 9%
38. Lung Neoplasms 8%
39. Denmark 8%
40. Mutation 8%
41. Polymerase Chain Reaction 8%
42. Homeobox Genes 8%
43. Disease-Free Survival 7%
44. DNA Mismatch Repair 7%
45. Adenocarcinoma 7%
46. Exons 7%
47. gemcitabine 6%
48. Neuropeptide Y 6%
49. regorafenib 6%
50. Systematic Reviews 6%